MedTrace Logo

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

NCT06161922 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-12-08

No results posted yet for this study

Summary

This is a non-interventional observational, multi-center cohort study to evaluate patient-reported outcomes in Chinese HER2+ early breast cancer patients undergoing (neo) adjuvant anti-HER2 based therapy and describe changes over time, from baseline to 12 months.

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Keda Yu, MD, PhD · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161922 on ClinicalTrials.gov